Berit X. Carlson, PhD | Psychiatrist.com

Article

A 52-Week, Double-Blind Evaluation of the Metabolic Effects of Aripiprazole and Lithium in Bipolar I Disorder

November 3, 2011

The current study assessed the long-term metabolic effects of aripiprazole monotherapy relative to lithium monotherapy for the treatment of bipolar I disorder.

Roger S. McIntyre, Susan L. McElroy, James M. Eudicone, et al

Original Research

Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163)

December 17, 2009

J. Craig Nelson, Michael E. Thase, Madhukar H. Trivedi, et al

Original Research

Adjunctive Aripiprazole in Major Depressive Disorder: Analysis of Efficacy and Safety in Patients With Anxious and Atypical Features

December 31, 2008

Madhukar H. Trivedi, Michael E. Thase, Maurizio Fava, et al

Original Research

Examining the Efficacy of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Analysis of 2 Studies

December 15, 2008

Michael E. Thase, Madhukar H. Trivedi, J. Craig Nelson, et al

Original Research

Aripiprazole Monotherapy for Maintenance Therapy in Bipolar I Disorder: A 100-Week, Double-Blind Study Versus Placebo

October 15, 2007

Joseph R. Calabrese, Roger S. McIntyre, Robert D. McQuade, et al

Original Research

A Randomized, Double-Blind, Placebo-Controlled 26-Week Trial of Aripiprazole in Recently Manic Patients With Bipolar I Disorder.

April 15, 2006

Joseph R. Calabrese, Robert D. McQuade, William H. Carson, et al